ASM commented on an FDA proposal to reclassify antigen based rapid influenza virus antigen detection test systems intended to detect influenza virus directly from clinical specimens.
The ASM sent a statement to ASM members on Dual Use Research of Concern and Biosafety.
The ASM sent a letter to Senator Tom Harkin thanking him for the Accelerating Biomedical Research Act and his leadership regarding funding for the National Institutes of Health.
The ASM has prepared a history related to select agents.
ASM provided comments to the Centers for Medicare & Medicaid Services (CMS) regarding Section 1834A, “Improving Policies for Clinical Diagnostic Laboratory Tests,” added to the Social Security Law by the Protecting Access to Medicare Act of 2014 (PAMA).